News Briefs

Premium

Cerenis Therapeutics Licenses HDL Therapy IP from Montreal Heart Institute

Cerenis Therapeutics said this week that it has licensed intellectual property from the Montreal Heart Institute Research Centre supporting the development of a drug for aortic valve stenosis based on high-density lipoprotein therapy.

The technology is based on the findings of Jean-Claude Tardif of MHIRC.

Cerenis, which has offices in Toulouse, France, and Ann Arbor, Mich., develops HDL-related compounds for treating cardiovascular and metabolic diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.